Evaluation of the protective effect of a new beta-agonist, KWD 2131, on allergen-induced bronchospasm.

Abstract

The selective anti-allergic effect of a new beta-agonist, KWD 2131, in inhibiting allergen-provoked asthma was compared with that of placebo in a double-blind crossover study. Non-bronchodilating doses were given by inhalation to 12 asymptomatic patients with extrinsic asthma. KWD 2131 showed a marginal anti-allergic effect. A significantly better effect than that with placebo was obtained at only one time of measurement after challenge (P < 0.05). The reproducibility of the allergen challenge was also evaluated. The mean maximum decrease in FEV1 during three different allergen-challenge procedures was 37, 31, and 38%, respectively. The difference was not statistically significant.

• Authors: B Hegardt, O Löwhagen, N Svedmyr
• Journal: Allergy (Allergy) Vol. 35 Issue 5 Pg. 413-9 (Jul 1980) ISSN: 0105-4538 [Print] Denmark
• PMID: 6108726 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Adrenergic beta-Agonists
• Allergens
• Placebos
• KWD 2131
• Terbutaline

Topics

• Adrenergic beta-Agonists (therapeutic use)
• Adult
• Allergens
• Asthma (drug therapy)
• Bronchial Provocation Tests
• Bronchial Spasm (drug therapy)
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Forced Expiratory Volume
• Humans
• Male
• Placebos
• Terbutaline (analogs & derivatives, therapeutic use)